Correction to: Eye (2015) 29, 342–349; doi:10.1038/eye.2014.258; published online 7 November 2014
Since the online publication of the above article, the authors have noted that Figure 3 is incorrect. Interval increased has been repeated and the wording below the diagonal line should be interval decreased. The corrected figure can be found below.
Distribution of the first measured interval after loading doses (horizontal axis), plotted against the last applied interval at month 24 (vertical axis), for all eyes that underwent treatment with ranibizumab for neovascular age-related macular degeneration according to the studied regimen ‘observe and plan’. The term ‘observation’ is equivalent to any interval longer than 3 months. These eyes were followed regularly without planned injection.
The authors would like to apologise for this error.
Additional information
The online version of the original article can be found at 10.1038/eye.2014.258
Rights and permissions
About this article
Cite this article
Gianniou, C., Dirani, A., Ferrini, W. et al. Erratum: Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye 29, 450–451 (2015). https://doi.org/10.1038/eye.2014.321
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2014.321
This article is cited by
-
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
Graefe's Archive for Clinical and Experimental Ophthalmology (2017)
-
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
BMC Ophthalmology (2016)
-
Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
Drugs & Aging (2015)
